Tipranks Press Release.
Results presented at ESMO show a promising therapeutic index for [212Pb]VMT-α-NETDurable disease control in all three cohorts and 72% PFS at 18 months across all patients who received at least one treatmentRobust activity observed at three dose levels across patient populations, with ORRs of 33% and 50% in Cohorts 2 and 3, respectively; higher responses were observed in Cohort 3 relative to Cohort 2 at early assessments [212Pb]VMT-α-NET continues to be well-tolerated, with no DLTs, and no discon
Tipranks Press Release.
Detailed price information for Perspective Therapeutics Inc (CATX-A) from The Globe and Mail including charting and trades.
Tipranks Press Release.
Detailed price information for Sarepta Therapeutics (SRPT-Q) from The Globe and Mail including charting and trades.
SEATTLE, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced a clinical trial collaboration agreement with Merck (NYSE: MRK), known as MSD outside of the United States and Canada. The agreement supports the evaluation of Perspective’s targeted alpha-particle therapy [212Pb]PSV359 in com
Perspective Therapeutics (CATX) has signed a clinical trial collaboration with Merck (MRK) for the p
SEATTLE, Sept. 11, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that updated data on the Company’s [212Pb]VMT-α-NET program have been accepted for presentation as detailed below at the 38th EORTC-NCI-AACR (ENA) Symposium 2026 on Molecular Targets and Cancer Therapeutics taking place Novemb
Detailed price information for Perspective Therapeutics Inc (CATX-A) from The Globe and Mail including charting and trades.
Perspective Therapeutics is rated Strong Buy on durable radiopharmaceutical data, $237M cash runway, and key 2026 catalysts. Click here to read more.
This is the newest page. Registered accounts read further back.